BR112017007428A2 - fatty acid and self-fatty acid ester compositions and their uses in the treatment of disease states - Google Patents

fatty acid and self-fatty acid ester compositions and their uses in the treatment of disease states

Info

Publication number
BR112017007428A2
BR112017007428A2 BR112017007428A BR112017007428A BR112017007428A2 BR 112017007428 A2 BR112017007428 A2 BR 112017007428A2 BR 112017007428 A BR112017007428 A BR 112017007428A BR 112017007428 A BR112017007428 A BR 112017007428A BR 112017007428 A2 BR112017007428 A2 BR 112017007428A2
Authority
BR
Brazil
Prior art keywords
fatty acid
compositions
disease
ester
omega
Prior art date
Application number
BR112017007428A
Other languages
Portuguese (pt)
Inventor
Abd Almalik Ahmed Mohammed Daak Ahmed
D Sancilio Frederick
DANIEL-ARCHIBALD Glynis
Lopez-Toledano Miguel
Thorsteinsson Thorsteinn
Original Assignee
Sancilio & Company Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54347886&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017007428(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sancilio & Company Inc filed Critical Sancilio & Company Inc
Publication of BR112017007428A2 publication Critical patent/BR112017007428A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

resumo "composições de éster de ácido graxo e ácidos graxos autocomnizantes e suas utilizações no tratamento de estados da doença" são aqui descritas composições que incluem pelo menos um ácido gordo omega-3 (quer na forma de triglicérido, éster ou éster de ácido gordo livre) e pelo menos um agente tensioactivo; em que as composições formam micelas quando em contacto com um meio aquoso. são também proporcionados métodos para ad-ministrar a um indivíduo uma composição que inclua pelo menos um ácido gordo omega-3 (quer na forma de triglicérido, éster ou éster de ácido gordo livre) e pelo menos um agente tensioactivo, em que as composições formam micelas quando em contacto com um meio aquoso, e a biodisponibilidade do ácido gordo ômega-3 é substancialmente independente de um efeito alimentar. as composições são úteis para o tratamento de certos estados patológicos que podem incluir (1) síndromes de má absorção, (2) colangite esclerosante primária (psc), (3) doença hepática gordu-rosa não alcoólica (nafld), (4) sickle cell disease (scd) , (5) a degeneração macu-lar relacionada com a idade (dmae) e (6) a doença neurodegenerativa, incluindo a doença de parkinson (pd), a doença de alzheimer (ad), a esclerose lateral amiotró-fica (als ou doença de lou gehrig), a epilepsia bipolar síndrome, lesão cerebral traumática, neuropatia periférica e esclerose múltipla (em). são descritas também várias formas de dosagem para administração das composições e utilização das composições em alimentos funcionais. são aqui fornecidos também kits com instru-ções para a sua administração.Abstract "Autocomponent fatty acid ester compositions and their uses in treating disease states" Compositions comprising at least one omega-3 fatty acid (either in the form of a free fatty acid triglyceride, ester or ester form) are described herein. ) and at least one surfactant; wherein the compositions form micelles when in contact with an aqueous medium. Also provided are methods of administering to a subject a composition comprising at least one omega-3 fatty acid (either as triglyceride, ester or free fatty acid ester) and at least one surfactant, wherein the compositions form micelles when in contact with an aqueous medium, and the bioavailability of omega-3 fatty acid is substantially independent of an eating effect. The compositions are useful for treating certain disease states which may include (1) malabsorption syndromes, (2) primary sclerosing cholangitis (psc), (3) nonalcoholic fatty liver disease (nafld), (4) sickle cell disease (scd), (5) age-related macular degeneration (dmae) and (6) neurodegenerative disease, including parkinson's disease (pd), alzheimer's disease (ad), amyotrophic lateral sclerosis -physical (als or lou gehrig's disease), bipolar epilepsy syndrome, traumatic brain injury, peripheral neuropathy and multiple sclerosis (em). Various dosage forms for administration of the compositions and use of the compositions in functional foods are also described. Also provided herein are instructions kits for their administration.

BR112017007428A 2014-10-10 2015-10-09 fatty acid and self-fatty acid ester compositions and their uses in the treatment of disease states BR112017007428A2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462062634P 2014-10-10 2014-10-10
US201462062643P 2014-10-10 2014-10-10
US201462062651P 2014-10-10 2014-10-10
US201462062638P 2014-10-10 2014-10-10
US201462062652P 2014-10-10 2014-10-10
US201462062646P 2014-10-10 2014-10-10
PCT/US2015/054933 WO2016057915A1 (en) 2014-10-10 2015-10-09 Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states

Publications (1)

Publication Number Publication Date
BR112017007428A2 true BR112017007428A2 (en) 2017-12-19

Family

ID=54347886

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017007428A BR112017007428A2 (en) 2014-10-10 2015-10-09 fatty acid and self-fatty acid ester compositions and their uses in the treatment of disease states

Country Status (8)

Country Link
EP (1) EP3212236A1 (en)
BR (1) BR112017007428A2 (en)
CA (1) CA2963952C (en)
CL (1) CL2017000867A1 (en)
MA (1) MA40846A (en)
MX (2) MX2017004324A (en)
WO (1) WO2016057915A1 (en)
ZA (1) ZA201702385B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106692973A (en) * 2015-11-13 2017-05-24 深圳君圣泰生物技术有限公司 Pharmaceutical compositions and applications thereof, and pharmaceutical preparation
CA3023648C (en) * 2016-05-10 2023-11-28 Shenzhen Hightide Biopharmaceutical, Ltd. Pharmaceutical composition of berberine with epa and dha
WO2018027278A1 (en) * 2016-08-12 2018-02-15 Pharmako Biotechnologies Pty Limited Omega-3 compositions and methods relating thereto
CN110312509A (en) * 2017-02-07 2019-10-08 费森尤斯卡比德国有限公司 Use the long-term efficacy of the liver disease of EPA and DHA
FR3092968B1 (en) * 2019-02-22 2021-05-21 Microphyt DIETARY SUPPLEMENT
IT201900007202A1 (en) * 2019-05-24 2020-11-24 Pavia Farm S R L COMPOSITION BASED ON LIPOSOLUBLE VITAMINS WITH HIGH ENTERIC ABSORPTION
EP4014758A4 (en) 2019-08-13 2023-08-16 Team Foods Colombia S.A. Lipid composition comprising antioxidants and natural polyphenols as a non-pharmacological alternative for the treatment and prevention of non-alcoholic fatty liver disease (nafld)
CN115737555B (en) * 2022-05-20 2024-06-21 深圳海王医药科技研究院有限公司 Cepharanthine self-microemulsion composition, preparation and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2762939C (en) * 2009-05-22 2017-07-18 Mochida Phamaceutical Co., Ltd. Self-emulsifying composition of .omega.3 fatty acid
AR082930A1 (en) * 2010-09-08 2013-01-16 Pronova Biopharma Norge As COMPOSITIONS THAT INCLUDE AN OILY MIXTURE OF FATTY ACIDS, A TENSIOACTIVE AND A STATIN
TW201343203A (en) * 2011-12-22 2013-11-01 Pronova Biopharma Norge As Gelatin/alginate delayed release capsules comprising omega-3 fatty acids, and methods and uses thereof
ES2741560T3 (en) * 2012-03-30 2020-02-11 Micelle Biopharma Inc Compositions of omega-3 fatty acid esters

Also Published As

Publication number Publication date
EP3212236A1 (en) 2017-09-06
MX2020002238A (en) 2020-07-13
CL2017000867A1 (en) 2017-11-03
CA2963952C (en) 2023-10-17
MX2017004324A (en) 2017-07-04
CA2963952A1 (en) 2016-04-14
ZA201702385B (en) 2020-12-23
WO2016057915A1 (en) 2016-04-14
MA40846A (en) 2017-09-05

Similar Documents

Publication Publication Date Title
BR112017007428A2 (en) fatty acid and self-fatty acid ester compositions and their uses in the treatment of disease states
CL2018001089A1 (en) Valbenazine salts and polymorphs thereof.
MX2019007586A (en) Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases.
BR112013018920A2 (en) nanoparticle compositions, formulations thereof and their uses
BR112019008458A2 (en) 1,2,4-triazolones 2,4,5-trisubstituted.
BR112017002221A2 (en) 2- (morpholin-4-yl) -1,7-naphthyridines
BR112016006926A2 (en) compositions comprising a quinic acid-caffeic acid conjugate, therapeutic and cosmetic uses
UY37460A (en) 1,2,4-TRIAZOLONS WITH ANALATION IN 4 AND 5
MX361858B (en) Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions.
BR112015021888A8 (en) dna-pk inhibitors, their uses and pharmaceutical composition
BR112015022041A2 (en) Substituted 3-phenylpropylamine derivatives for the treatment of ophthalmic diseases and disorders
BR112018067946A2 (en) topical formulations containing cyclosporine and their uses
WO2017053868A8 (en) C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses
BR112017004173A2 (en) compound, pharmaceutical composition, and method for treating a disease or condition.
TR201904514T4 (en) Macrocyclic LRRK2 kinase inhibitors.
UY35276A (en) New compounds that inhibit the activity of Lp-PLA2
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
MX2016015211A (en) Topical formulations and uses thereof.
WO2014160871A3 (en) Methods and agents for treating alzheimer's disease
BR112014030534A2 (en) galacto-ramnogalacturonate compositions for the treatment of diseases associated with high inducible nitric oxide synthase
CY1123942T1 (en) OMEGA-3 FATTY ACID COMPOSITIONS FOR THE TREATMENT OF DISEASES CAUSING DAMAGE TO THE NERVOUS SYSTEM
BR112019006880A2 (en) compounds and compositions for treating leishmaniasis and methods of diagnosis and treatment using the same
BR112015010271A8 (en) Comicronization product, process for the preparation of a comicronization product, pharmaceutical composition and its uses
BR112015014367A2 (en) lfa-1 inhibitor formulations
BR112017021583A2 (en) Methods for treating inflammatory disorders

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 11.2 NA RPI NO 2640 DE 10/08/2021 POR TER SIDO INDEVIDA.